688176 Stock Overview
Engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Jiangsu Yahong Meditech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥7.91 |
| 52 Week High | CN¥8.58 |
| 52 Week Low | CN¥4.71 |
| Beta | 0.65 |
| 1 Month Change | 20.95% |
| 3 Month Change | 8.06% |
| 1 Year Change | 20.95% |
| 3 Year Change | -48.80% |
| 5 Year Change | n/a |
| Change since IPO | -55.06% |
Recent News & Updates
Shareholder Returns
| 688176 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 6.5% | 0.4% | 1.3% |
| 1Y | 20.9% | 1.9% | 16.8% |
Return vs Industry: 688176 exceeded the CN Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: 688176 exceeded the CN Market which returned 16.8% over the past year.
Price Volatility
| 688176 volatility | |
|---|---|
| 688176 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 5.0% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in CN Market | 10.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688176 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688176's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 411 | Kevin Pan | www.asieris.cn |
Jiangsu Yahong Meditech Co., Ltd. engages in the research and development, production, and commercialization of drugs for genitourinary system tumors and other diseases in China and internationally. Its pipeline includes APL-1202, an anti-tumor drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; APL-1501, an oral MetAP inhibitor that is in Phase I clinical trial for the treatment of urinary system tumors and drug-resistant urinary tract infections; APL-1706, an agent drug, which is in Phase III clinical trial for the treatment of non-muscle invasive bladder cancer; and APL-1702, a photodynamic therapy product that is in Phase III clinical trial for the treatment of cervical high-grade squamous intraepithelial lesions of the cervix caused by infection of HPV subtypes. In addition, it develops targeted protein degraders which are in preclinical stage comprising ASN-1764 for the treatment of triple negative breast cancer; ASN-1780 for the treatment of metastatic castration-resistant prostate cancer; and APL-1901 for the treatment of ER positive breast cancer.
Jiangsu Yahong Meditech Co., Ltd. Fundamentals Summary
| 688176 fundamental statistics | |
|---|---|
| Market cap | CN¥4.44b |
| Earnings (TTM) | -CN¥403.23m |
| Revenue (TTM) | CN¥149.71m |
29.7x
P/S Ratio-11.0x
P/E RatioIs 688176 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688176 income statement (TTM) | |
|---|---|
| Revenue | CN¥149.71m |
| Cost of Revenue | CN¥30.99m |
| Gross Profit | CN¥118.72m |
| Other Expenses | CN¥521.95m |
| Earnings | -CN¥403.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Apr 19, 2025
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 79.30% |
| Net Profit Margin | -269.34% |
| Debt/Equity Ratio | 3.2% |
How did 688176 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 23:01 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jiangsu Yahong Meditech Co., Ltd. is covered by 6 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jin Zhang | China International Capital Corporation Limited |
| null null | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |